Immunostaining for the tumour suppressor gene p16 product is a useful marker to differentiate melanoma metastasis from lymph-node nevus
- PMID: 14576937
- DOI: 10.1007/s00428-003-0897-9
Immunostaining for the tumour suppressor gene p16 product is a useful marker to differentiate melanoma metastasis from lymph-node nevus
Abstract
Upon the introduction of extensive sampling protocols of sentinel node biopsies, pathologists are increasingly confronted with small melanoma metastases. Using conventional histology, it proves sometimes difficult or impossible to differentiate small melanoma metastases from lymph-node nevi. Loss of the tumour suppressor gene p16 has been shown to be associated with tumour progression of melanoma. We investigated nevus and melanoma cells for the presence of the product of the gene p16, using immunohistochemistry. All nevus cells, independent of their location (nodal or skin) displayed an extensive nuclear and cytoplasmic staining for p16. In contrast, all cells of melanoma metastases, except one skin metastasis, lacked nuclear staining for p16. These findings indicate that p16 is a reliable marker to distinguish lymph-node nevi from melanoma metastasis.
Similar articles
-
5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsies.Mod Pathol. 2015 Feb;28(2):218-29. doi: 10.1038/modpathol.2014.99. Epub 2014 Aug 1. Mod Pathol. 2015. PMID: 25081754 Free PMC article.
-
Lymph node melanocytic nevi: pathogenesis and differential diagnoses, with special reference to p16 reactivity.Pathol Res Pract. 2015 May;211(5):381-8. doi: 10.1016/j.prp.2015.01.003. Epub 2015 Jan 21. Pathol Res Pract. 2015. PMID: 25661066
-
The diagnostic utility of PRAME and p16 in distinguishing nodal nevi from nodal metastatic melanoma.Pathol Res Pract. 2020 Sep;216(9):153105. doi: 10.1016/j.prp.2020.153105. Epub 2020 Jul 11. Pathol Res Pract. 2020. PMID: 32825968
-
Nevus cell aggregates massively occupying parenchyma of an external iliac lymph node: A case report and review of the literature.J Cutan Pathol. 2020 Dec;47(12):1175-1180. doi: 10.1111/cup.13805. Epub 2020 Sep 10. J Cutan Pathol. 2020. PMID: 32644206 Review.
-
Sentinel lymph nodes in cutaneous melanoma.Clin Lab Med. 2011 Jun;31(2):301-10. doi: 10.1016/j.cll.2011.03.007. Clin Lab Med. 2011. PMID: 21549243 Review.
Cited by
-
Issues affecting molecular staging in the management of patients with melanoma.J Cell Mol Med. 2007 Sep-Oct;11(5):1052-68. doi: 10.1111/j.1582-4934.2007.00091.x. J Cell Mol Med. 2007. PMID: 17979882 Free PMC article. Review.
-
Cutaneous Melanomas: A Single Center Experience on the Usage of Immunohistochemistry Applied for the Diagnosis.Int J Mol Sci. 2022 May 25;23(11):5911. doi: 10.3390/ijms23115911. Int J Mol Sci. 2022. PMID: 35682589 Free PMC article. Review.
-
5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsies.Mod Pathol. 2015 Feb;28(2):218-29. doi: 10.1038/modpathol.2014.99. Epub 2014 Aug 1. Mod Pathol. 2015. PMID: 25081754 Free PMC article.
-
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma.Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1713-42. doi: 10.1007/s00259-009-1228-4. Eur J Nucl Med Mol Imaging. 2009. PMID: 19714329
-
Immune-phenotypical markers for the differential diagnosis of melanocytic lesions.Int J Clin Exp Pathol. 2015 Sep 1;8(9):9742-51. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26617684 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical